Spero Therapeutics Inc (SPRO)
0.9367
+0.01
(+1.51%)
USD |
NASDAQ |
Dec 24, 13:00
0.9367
0.00 (0.00%)
After-Hours: 13:59
Spero Therapeutics Cash from Financing (Quarterly): 0.00 for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Financing (Quarterly) Benchmarks
| CytomX Therapeutics Inc | 0.00 |
| Castle Biosciences Inc | 0.838M |
| Arbutus Biopharma Corp | 1.775M |
| PTC Therapeutics Inc | -17.63M |
| Equillium Inc | 0.00 |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 12.76M |
| Free Cash Flow | -17.54M |
| Free Cash Flow Per Share (Quarterly) | 0.2358 |
| Free Cash Flow to Equity (Quarterly) | 12.76M |
| Free Cash Flow to Firm (Quarterly) | 12.76M |
| Free Cash Flow Yield | -34.71% |